Children's of Alabama, Birmingham, AL, USA.
Adv Exp Med Biol. 2024;1448:553-563. doi: 10.1007/978-3-031-59815-9_36.
Interleukin-1 is a prototypic proinflammatory cytokine that is elevated in cytokine storm syndromes (CSSs), such as secondary hemophagocytic lymphohistiocytosis (sHLH) and macrophage activation syndrome (MAS). IL-1 has many pleotropic and redundant roles in both innate and adaptive immune responses. Blockade of IL-1 with recombinant human interleukin-1 receptor antagonist has shown efficacy in treating CSS. Recently, an IL-1 family member, IL-18, has been demonstrated to be contributory to CSS in autoinflammatory conditions, such as in inflammasomopathies (e.g., NLRC4 mutations). Anecdotally, recombinant IL-18 binding protein can be of benefit in treating IL-18-driven CSS. Lastly, another IL-1 family member, IL-33, has been postulated to contribute to CSS in an animal model of disease. Targeting of IL-1 and related cytokines holds promise in treating a variety of CSS.
白细胞介素-1 是一种典型的促炎细胞因子,在细胞因子风暴综合征 (CSS) 中升高,如继发性噬血细胞性淋巴组织细胞增生症 (sHLH) 和巨噬细胞活化综合征 (MAS)。IL-1 在先天和适应性免疫反应中具有许多多效性和冗余作用。用重组人白细胞介素-1 受体拮抗剂阻断 IL-1 已被证明在 CSS 的治疗中有效。最近,IL-1 家族成员 IL-18 已被证明在自身炎症性疾病中有助于 CSS,例如在炎性体病(例如 NLRC4 突变)中。据报道,重组 IL-18 结合蛋白可有益于治疗由 IL-18 驱动的 CSS。最后,另一种 IL-1 家族成员 IL-33 被假设在疾病的动物模型中有助于 CSS。针对 IL-1 和相关细胞因子有望治疗各种 CSS。